Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 2
1984 1
1990 2
1991 7
1992 2
1993 4
1994 1
1995 3
1996 5
1997 4
1998 2
1999 6
2000 6
2001 6
2002 8
2003 4
2004 10
2005 7
2006 11
2007 19
2008 11
2009 7
2010 9
2011 22
2012 26
2013 19
2014 20
2015 14
2016 9
2017 25
2018 19
2019 13
2020 20
2021 16
2022 18
2023 18
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

338 results

Results by year

Filters applied: . Clear all
Page 1
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KJ, Armenian S, Nwangwu M, Lee PP, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry A, Rosen S, Kwak L, Forman SJ, Herrera AF. Mei MG, et al. Among authors: kwak l. Blood. 2022 Jun 23;139(25):3605-3616. doi: 10.1182/blood.2022015423. Blood. 2022. PMID: 35316328 Free PMC article. Clinical Trial.
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Herrera AF, et al. Among authors: kwak lw. Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17. Lancet Haematol. 2023. PMID: 36403579 Clinical Trial.
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J. McGregor BA, et al. Among authors: kwak l. Ann Oncol. 2024 Jan;35(1):91-97. doi: 10.1016/j.annonc.2023.09.3114. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871703 Clinical Trial.
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Mei M, Chen L, Godfrey J, Song J, Egelston C, Puverel S, Budde LE, Armenian S, Nikolaenko L, Nwangwu M, Guo W, Gao L, Lee P, Chen R, Daniels S, Kennedy N, Peters L, Zain J, Rosen S, Forman S, Popplewell L, Kwak L, Herrera AF. Mei M, et al. Among authors: kwak l. Blood. 2023 Oct 19;142(16):1359-1370. doi: 10.1182/blood.2023020485. Blood. 2023. PMID: 37339586
Targeting myeloid-derived suppressor cells for cancer immunotherapy.
Liu Y, Wei G, Cheng WA, Dong Z, Sun H, Lee VY, Cha SC, Smith DL, Kwak LW, Qin H. Liu Y, et al. Among authors: kwak lw. Cancer Immunol Immunother. 2018 Aug;67(8):1181-1195. doi: 10.1007/s00262-018-2175-3. Epub 2018 May 31. Cancer Immunol Immunother. 2018. PMID: 29855694 Review.
Lymphomas.
Kwak LW, DeVita VT Jr, Longo DL. Kwak LW, et al. Cancer Chemother Biol Response Modif. 1994;15:413-70. Cancer Chemother Biol Response Modif. 1994. PMID: 7779591 Review. No abstract available.
The Role of Federated Learning Models in Medical Imaging.
Kwak L, Bai H. Kwak L, et al. Radiol Artif Intell. 2023 May 31;5(3):e230136. doi: 10.1148/ryai.230136. eCollection 2023 May. Radiol Artif Intell. 2023. PMID: 37293343 Free PMC article. No abstract available.
338 results